Forte Biosciences (FBRX) Free Cash Flow Growth (3y) (2019 - 2026)
Forte Biosciences (FBRX) Free Cash Flow Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,094.26 Bn | 68,093.97 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,939.09 Bn | 1,939.02 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 123.34 Bn | 116.09 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.38 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - | - |
| 8 | Argenx Se | 56.38 Bn | 51.20 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 31.42% |
| 10 | Forte Biosciences | 1.36 Bn | 1.30 Bn | - | -53.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.44% |
| Dec 31, 2025 | -78.61% |
| Sep 30, 2025 | -93.50% |
| Jun 30, 2025 | -94.04% |
| Mar 31, 2025 | -74.06% |
| Dec 31, 2024 | -40.99% |
| Sep 30, 2024 | -16.63% |
| Jun 30, 2024 | -14.66% |
| Mar 31, 2024 | -18.31% |
| Dec 31, 2023 | -33.19% |
| Sep 30, 2023 | -5.54% |
| Jun 30, 2023 | -10.88% |
| Mar 31, 2023 | -22.01% |
| Dec 31, 2022 | -57.39% |
| Sep 30, 2022 | -48.79% |
| Jun 30, 2022 | -27.76% |
| Mar 31, 2022 | 51.86% |
| Dec 31, 2021 | 32.44% |
| Sep 30, 2021 | -80.65% |
| Jun 30, 2021 | 30.23% |